Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
26.10
+0.40 (1.56%)
May 8, 2025, 11:29 AM - Market open

Revenue by Product

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Novel Immunotherapies
10.59M
Log In
Log In
Log In
Novel Immunotherapies Growth
30.99%
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
United States
10.59M
Log In
Log In
Log In
United States Growth
30.99%
Log In
Log In
Log In